Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122533) titled 'Phase II Prospective Single-Arm Study of Ivonescimab plus Re-irradiation in Patients with Recurrent High-Grade Glioma: Efficacy and Safety Assessment' on April 14.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Sichuan Cancer Hospital
Condition:
High-Grade Glioma
Recruitment Status: Recruiting
Phase: 2
Date of First Enrollment: 2026-04-15
Target Sample Size: Intervention group:21;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=309422
Disclaimer: Curated by HT Syndication....